bioAffinity Technologies maintains CAP accreditation for lab subsidiary PPLS

bioAffinity Technologies, Inc.

Precision Pathology Laboratory Services (PPLS) passed rigorous CAP on-site inspection, retaining gold-standard accreditation.
Reaffirms quality, accuracy, and patient safety for CyPath Lung test and all lab services lines.
CEO states ongoing CAP accreditation supports value proposition with physicians, health systems, and partners.
Lung cancer diagnostics market projected to grow from $4.8B (2024) to $10.4B by 2034 at 8.1% CAGR.
CyPath Lung test demonstrates 92% sensitivity, 87% specificity, 88% accuracy in detecting early-stage lung cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.